KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients

Biomedicine and Pharmacotherapy

Volumn 65, Issue 1, 2011, Pages 22-26

  Xu, Rui Feng ^a   Sun, Ji Ping ^a   Zhang, Shi Rong ^b   Zhu, Guan Shan ^b   Li, Li Bo ^a   Liao, Yu Lin ^a   Xie, Jian Ming ^a   Liao, Wang Jun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Biliary tract cancer; BRAF; KRAS; PIK3CA

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PATIENT; CANCER STAGING; CHINESE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MALE; MUTATIONAL ANALYSIS; ONCOGENE; PRIORITY JOURNAL; SOMATIC MUTATION;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 79951677877     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.06.009     Document Type: Article

References (32)

1. Shaib Y., El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004, 24:115-125.
2. Malhi H., Gores G.J. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006, 45:856-867.
3. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52:706-712.
4. Riener M.O., Bawohl M., Clavien P.A., Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 2008, 47:363-367.
5. McKay M.M., Morrison D.K. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007, 26:3113-3121.
6. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
7. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
8. Carracedo A., Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27:5527-5541.
9. Prenen H., De Schutter J., Jacobs B., De Roock W., Biesmans B., Claes B. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009, 15:3184-3188.
10. Laurent-Puig P., Lievre A., Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009, 15:1133-1139.
11. Perrone F., Lampis A., Orsenigo M., Di Bartolomeo M., Gevorgyan A., Losa M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009, 20:84-90.
12. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
13. Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M., McLendon R.E., et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004, 64:5048-5050.
14. Wang Y., Helland A., Holm R., Kristensen G.B., Borresen-Dale A.L. PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005, 25:322.
15. Watanabe M., Asaka M., Tanaka J., Kurosawa M., Kasai M., Miyazaki T. Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology 1994, 107:1147-1153.
16. Pratilas C.A., Solit D.B. Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials 2007, 2:121-134.
17. Arcaro A., Guerreiro A.S. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics 2007, 8:271-306.
18. Nagasaka T., Sasamoto H., Notohara K., Cullings H.M., Takeda M., Kimura K., et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004, 22:4584-4594.
19. Board R.E., Thelwell N.J., Ravetto P.F., Little S., Ranson M., Dive C., et al. Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 2008, 54:757-760.
20. Gymnopoulos M., Elsliger M.A., Vogt P.K. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 2007, 104:5569-5574.
21. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007, 67:2643-2648.
22. Roa J.C., Anabalon L., Tapia O., Melo A., de Aretxabala X., Roa I. [Frequency of K-ras mutation in biliary and pancreatic tumors]. Rev Med Chil 2005, 133:1434-1440.
23. Rashid A, Ueki T., Gao Y.T., Houlihan P.S., Wallace C., Wang B.S., et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 2002, 8:3156-3163.
24. Kiba T., Tsuda H., Pairojkul C., Inoue S., Sugimura T., Hirohashi S. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993, 8:312-318.
25. Hakimi M.A., Bochar D.A., Chenoweth J., Lane W.S., Mandel G., Shiekhattar R. A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc Natl Acad Sci U S A 2002, 99:7420-7425.
26. Yoshikawa D., Ojima H., Kokubu A., Ochiya T., Kasai S., Hirohashi S., et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 2009, 100:1257-1266.
27. Jinawath A., Akiyama Y., Sripa B., Yuasa Y. Dual blockade of the hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol 2007, 133:271-278.
28. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
29. Lievre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
30. Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64:7678-7681.
31. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
32. Goldenberg D., Rosenbaum E., Argani P., Wistuba I.I., Sidransky D., Thuluvath P.J., et al. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol 2004, 17:1386-1391.